Repertoire Immune Medicines
Par un écrivain mystérieux
Description
Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease.
Our proprietary DECODE platform is designed to provide a comprehensive understanding of the full repertoire of interactions between T cell receptors and their antigen targets that take place when diseased cells are present. This complex and intricate biological process is known as the immune synapse. We believe the ability to decipher these interactions represents one of the greatest opportunities for innovation in medical science.
Repertoire's team operates from sites in Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases.
To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com.
Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets
Repertoire Immune Medicines — GYPSIES TRAMPS + THIEVES
Repertoire Immune Medicines on X: Repertoire celebrates #pride and is committed to being a company where diversity, equity, and inclusion are at our core #PrideMonth; #inclusion / X
Repertoire Immune Medicines on X: We are thrilled to welcome Anne Walker, Executive Director and Chief Financial Officer to Repertoire! Learn more here: #biotech #CFO #leadership #executive #drugdevelopment
Repertoire Immune Medicines on X: Repertoire Immune Medicines enters collaboration on novel antigen discovery and T cell receptor research in multiple sclerosis. Read more here: #multiplesclerosis #MS #biotechnews
Repertoire Immune Medicines (@RepertoireIM) / X
Andy Hurwitz, PhD • Repertoire Immune Medicines
Repertoire Immune Medicines (@RepertoireIM) / X
Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets
depuis
par adulte (le prix varie selon la taille du groupe)
